ROP

Analyst Note: Roper Technologies, Inc. (ROP)

Date: 2026-06-20 Current Price: $330.26

1. Structural Readiness

State: Forming Conservative Entry: — (Awaiting confirmed breakout above the coil high) Aggressive/Pre-Breakout Entry: — (Not actionable on setup alone; requires confirmation) Breakout Level: — (Defined by the high of the current consolidation range) Current Price: $330.26 Extension: — (Price is within the consolidation range, not extended above the breakout level) ATR Current: 2.9% (Productive) ATR at Breakout: — (Not yet established)

2. Thesis Layer

Thesis Classification: TACTICAL / Setup-Led Macro Thesis Status: None. Analysis: As of 2026-06-20, there is no named secular macro thesis driving this specific trade. The investment case is strictly setup-led, relying on the quality of the technical structure (the forming coil) combined with the underlying business fundamentals. We are not assigning a macro theme (e.g., "AI Supercycle" or "Industrial Reflation") to this name. The conviction must be derived entirely from the structural integrity of the setup and the strength of the company's operational execution as reported in the evidence base.

3. Business Overview

Company Description: Roper Technologies is a diversified technology company operating in vertical software and technology-enabled products. It serves defensible niche markets with market-leading businesses. Business Model: The company generates revenue through recurring software subscriptions (SaaS) and technology-enabled products, supported by a disciplined capital allocation strategy involving organic growth and strategic acquisitions. Industry: Industrials (specifically Software & Technology Enabled Products). Segment Breakdown (as of Q1 2026):

• Application Software: The largest segment, representing 56.7% of total net revenues in 2025. In Q1 2026, this segment grew 11.5% to $1,191.5 million, with 5.2% organic growth driven by legal, project-based private sector, higher education, and P&C insurance markets.
• Network Software: Represents 20.3% of 2025 revenues. Q1 2026 net revenues grew 13.8% to $427.6 million, with 5.2% organic growth in freight, construction, and alternate site healthcare markets.
• Technology Enabled Products: Represents 23.0% of 2025 revenues. Q1 2026 net revenues grew 8.5% to $476.2 million, with 7.1% organic growth led by medical products (precision measurement and airway management).

Operational Highlights (Evidence E1-E12):

• Growth Trajectory: Management expects organic growth for the balance of 2026 to be in the "mid-single-digit plus range" (E3).
• AI Integration: The company reports that AI is a meaningful growth driver. Specific examples include AI-generated session notes reducing time from 5-10 minutes to 30 seconds for clinicians (E5) and new AI-enabled product capabilities released by portfolio companies like CentralReach, ConstructConnect, and Vertafore (E4).
• Backlog Strength: As of March 31, 2026, total remaining performance obligations were $5,284.5 million. The backlog (revenue expected in the next 12 months) increased 11.8% to $3,392.1 million, driven by acquisitions and organic growth (E8, E9).
• Capital Allocation: The company has $5 billion of firepower available over the next 12 months for M&A and $3.8 billion of remaining share repurchase authorization (E7).

4. Archetype and Conviction

Archetype: Quality Compounder Fit Analysis: Roper fits the "Quality Compounder" archetype due to its consistent track record of compounding cash flow, increasing shareholder value, and operating in defensible niche markets (E15, E22). The business model is characterized by high barriers to entry, recurring revenue streams, and a history of successful M&A integration (e.g., CentralReach, Subsplash).

Conviction Stack:

• Thesis Strength: Low (Tactical only; no macro tailwind).
• Evidence Quality: High. The evidence base is robust, featuring recent earnings transcripts (April 2026) and SEC filings (May 2026) confirming guidance, backlog growth, and segment performance.
• Setup Readiness: Partial. The setup is not yet actionable for a conservative entry. It requires a confirmed breakout above the coil high to transition to "Confirmed-Active."
• Rerating Potential: Moderate. The combination of raised EPS guidance ($21.80–$22.05) and strong backlog growth suggests fundamental support for a multiple expansion if the technical breakout occurs.

Valuation Context: While specific P/E ratios are not provided in the evidence, the raised full-year EPS guidance to a midpoint of $22.05 (up $0.50) implies management confidence in earnings power. The current price of $330.26 implies a forward multiple that must be weighed against the 11.8% backlog growth and mid-single-digit organic growth expectations.

5. Invalidations, Strengths, and Gaps

What Would Strengthen the Case:

• Technical: A confirmed daily close above the high of the current forming coil (breakout).
• Fundamental: Continued acceleration in organic growth rates or further expansion of the backlog beyond the 11.8% growth seen in Q1.
• M&A: Successful deployment of the $5 billion M&A pipeline with accretive returns.

What Would Invalidate the Case:

• Fundamental: A significant miss on the raised EPS guidance or a contraction in the backlog.
• Macro/Operational: A slowdown in the vertical software markets (legal, healthcare, construction) that drives the organic growth.

Gaps in Evidence:

• Specific Valuation Metrics: The evidence does not provide the current P/E ratio or EV/EBITDA multiple to assess if the stock is cheap or expensive relative to its growth.
• Margin Trends: While revenue growth is detailed, specific operating margin expansion or contraction data for Q1 2026 is not explicitly quantified in the provided evidence (though implied by the "quality compounder" archetype).
• Debt Levels: The evidence mentions an unsecured credit facility but does not detail the current leverage ratio or debt maturity schedule.

PRIVATE ANALYST CALL

Judgment: Buy Confidence: medium Key evidence: Raised full-year EPS guidance to $21.80-$22.05; Backlog increased 11.8% to $3.39B in Q1 2026; Strong organic growth across all three segments (5.2%-7.1%); $5B M&A firepower available. Key risks: Technical setup is "forming" not "confirmed" (requires breakout); No named macro thesis to provide tailwinds; Potential for M&A integration issues or margin compression; Valuation sensitivity if growth slows. Sizing hint: Position size should reflect the "forming" status; smaller than a confirmed breakout trade, sized for the probability of a successful coil completion. Expected path: Management expects mid-single-digit organic growth for the balance of 2026; structural implication is that if the coil breaks out, the stock will likely re-rate based on the raised earnings trajectory. Expected horizon: 3 to 6 months for the technical setup to resolve (breakout or invalidation).